Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €57.55 EUR
Change Today -0.79 / -1.35%
Volume 2.6K
4AB On Other Exchanges
New York
EN Paris
As of 3:38 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (4AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - €59.50
52 Week Low
04/28/14 - €35.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBVIE INC (4AB)

abbvie inc (4AB) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

26,000 Employees
Last Reported Date: 02/20/15
Founded in 2012

abbvie inc (4AB) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (4AB) Key Developments

Japanese Ministry of Health, Labour and Welfare Grants Priority Review for Abbvie Inc.'s Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan

AbbVie Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir. This all-oral treatment is interferon (IFN) and ribavirin (RBV)-free and will be dosed once daily. The MHLW grants priority review to certain medicines on the basis of clinical usefulness and severity of the disease, including diseases like hepatitis C, which affects approximately 1.5 to 2 million people in Japan.1AbbVie's investigational hepatitis C treatment was submitted for marketing approval in Japan in February 2015. The New Drug Application is for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection and is supported by the Phase 3 GIFT-I study in Japanese genotype 1b (GT1b) HCV patients. AbbVie studied a two direct-acting antiviral treatment regimen without RBV in Japan due to patient and viral characteristics specific to the Japanese population, including high prevalence of GT1b. In Japan, GT1 is the most common HCV genotype and accounts for 60% to 70% of all patients infected with HCV.2 Of those patients, about 95% are infected with the GT1b sub-type. For the treatment of genotype 1 chronic hepatitis C virus (HCV) infection in Japan, AbbVie's investigational, two direct-acting antiviral treatment consists of the fixed-dosed combination of paritaprevir/ritonavir (150/100 mg) with ombitasvir (25 mg), dosed once daily. AbbVie's chronic HCV treatment combines two direct-acting antivirals, each with a distinct mechanism of action that targets and inhibits specific HCV proteins of the viral replication process. AbbVie's HCV clinical development program in Japan focuses on its investigational, two direct-acting antiviral treatment and is designed to achieve high SVR rates in chronic HCV infected patients, including additional genotypes and patients with compensated cirrhosis.

AbbVie Inc. Enters into 364-Day Bridge Term Loan Credit Agreement

On March 27, 2015, AbbVie Inc. entered into a 364-Day Bridge Term Loan Credit Agreement with the various financial institutions named therein, as lenders, and Morgan Stanley Senior Funding Inc., as administrative agent for the lenders, related to the previously announced Agreement and Plan of Merger, dated as of March 4, 2015 and amended as of March 22, 2015, among the company, Pharmacyclics Inc. and certain affiliates of the company. The Bridge Loan Agreement provides for an $18.0 billion term facility under which, subject to the satisfaction or valid waiver of certain conditions, the company may request up to two borrowings: one in an amount up to $18.0 billion on the first date on which the Acquisition is consummated and each of the conditions to funding of the Bridge Loan Agreement have been satisfied or validly waived and one on any date within 60 days after the Bridge Closing Date in an amount up to the lesser of $6.0 billion and the amount of the $18.0 billion commitment remaining after any amount requested on the Bridge Closing Date. The company may use the proceeds of any borrowings under the Bridge Loan Agreement to finance, among other things, the acquisition of Pharmacyclics pursuant to the Merger Agreement and payment of related fees and expenses, the repurchase of company common stock in connection with the acquisition of Pharmacyclics, and certain other permitted uses. Loans under the Bridge Loan Agreement mature 364 days after the Bridge Closing Date. The company's borrowings under the Bridge Loan Agreement will bear interest, at the company's option, based on either a base rate or a Eurocurrency (or LIBOR) rate. The base rate is equal to the high of the federal funds rate plus 0.50%, the rate of interest per annum from time to time published in the Money Rates section of The Wall Street Journal as being the Prime Lending Rate and the one-month Eurocurrency rate plus 1.00%. The margins on both base rate loans and Eurocurrency loans will increase at specified dates in accordance with the terms of the Bridge Loan Agreement. The Bridge Loan Agreement contains customary representations, warranties and affirmative and negative covenants, including a financial covenant limiting the Company's ratio of Consolidated Total Debt to Consolidated EBITDA to certain ratios on certain dates.

European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA (Daclizumab High-Yield Process) for Treatment of MS

Biogen and AbbVie announced that the European Medicines Agency has validated the companies’ Marketing Authorisation Application (MAA) for ZINBRYTA (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The MAA included results from two clinical trials, DECIDE and SELECT, in which ZINBRYTA 150 mg was administered subcutaneously every four weeks in people with relapsing-remitting MS. ZINBRYTA (daclizumab high-yield process) is an investigational drug and a new form of a humanized monoclonal antibody that selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25) that is expressed at high levels on T-cells that become abnormally activated in multiple sclerosis (MS). ZINBRYTA modulates IL-2 signaling without causing general immune cell depletion. ZINBRYTA is believed to work by decreasing abnormally-activated T-cells and pro-inflammatory lymphoid tissue inducer cells, and increasing CD56bright natural killer (NK) cells, which are important cells that help regulate the immune system. Biogen and AbbVie are jointly developing ZINBRYTA.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4AB:GR €57.55 EUR -0.79

4AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.25 USD -0.27
Amgen Inc $163.58 USD -3.29
Bristol-Myers Squibb Co $65.35 USD +1.67
Eli Lilly & Co $72.47 USD -1.02
Medtronic PLC $76.49 USD -0.53
View Industry Companies

Industry Analysis


Industry Average

Valuation 4AB Industry Range
Price/Earnings 56.8x
Price/Sales 5.0x
Price/Book 56.9x
Price/Cash Flow 55.9x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at